OncoZenge (8LY) Stock Overview
A pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
8LY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
OncoZenge AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.47 |
| 52 Week High | SEK 0.67 |
| 52 Week Low | SEK 0.34 |
| Beta | 1.44 |
| 1 Month Change | -23.53% |
| 3 Month Change | -0.43% |
| 1 Year Change | 2.63% |
| 3 Year Change | -20.68% |
| 5 Year Change | n/a |
| Change since IPO | -63.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8LY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -10.2% | -9.0% | -0.6% |
| 1Y | 2.6% | 18.3% | 9.7% |
Return vs Industry: 8LY underperformed the German Pharmaceuticals industry which returned 16.8% over the past year.
Return vs Market: 8LY underperformed the German Market which returned 7.7% over the past year.
Price Volatility
| 8LY volatility | |
|---|---|
| 8LY Average Weekly Movement | 11.7% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 8LY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8LY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1 | Stian Kildal | oncozenge.com |
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.
OncoZenge AB (publ) Fundamentals Summary
| 8LY fundamental statistics | |
|---|---|
| Market cap | €6.17m |
| Earnings (TTM) | -€809.40k |
| Revenue (TTM) | €263.30k |
Is 8LY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8LY income statement (TTM) | |
|---|---|
| Revenue | SEK 2.78m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 2.78m |
| Other Expenses | SEK 11.34m |
| Earnings | -SEK 8.55m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 18, 2026
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 100.00% |
| Net Profit Margin | -307.40% |
| Debt/Equity Ratio | 80.6% |
How did 8LY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/02 13:24 |
| End of Day Share Price | 2026/02/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OncoZenge AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |
| Johan Unnerus | Redeye |